Korea Research Institute of Bioscience and Biotechnology

Enzychem Lifesciences Corporation

Yungjin Pharmaceutical Co., Ltd.

Dongguk University Industry-academic Cooperation Foundation

Korea Institute of Oriental Medicine

Binex Co., Ltd.

Kyung Seop Ahn

Sei Ryang Oh

Hyeong Kyu Lee

Jung Hee Kim

Doo Young Kim

Ok-Kyoung Kwon

Jae Wha Kim

Sei-Ryang Oh

Joong Ku Lee

In Sik Shin

Ho Bum Kang

Ok Kyoung Kwon

Yong-Hae Han

Hyung Won Ryu

Mi Jin Kim

Ki Young Sohn

Su Ui Lee

Tae-Suk Lee

Hyouk Joung

JongKoo Kang

Sang Ku Lee

Seung Hyung Kim

Gui Hua Quan

Bo Young Park

Sang Ho Choi

Sang Woo Lee

Doo-Young Kim

Ki-Young Sohn

Tae Suk Lee

Jae Sung Song

Jong Koo Kang

Hyuk Hwan Song

Semi Kim

Ji-seok Yoo

Dae-hee Shin

Byung-hwan Ryoo

Yongnam Lee

Myung Hwan Kim

Young-Sik Jung

Hye Kyung Kim

Joo Heon Kim

Jae Min Shin

Soon Ja Choi

Hang Jin

Wan Yi Li

Young Eun Ko

Da Jung Ji

Ha Young Jang

Na-Rae Shin

Mee-Young Lee

SuUi Lee

Hwa-Young Son

Kyoung-youl Lee

Ji Won Park

So Young Kim

Kyeong Seok Lee

Gyoon Hee Han

Hee Gu Lee

Young Sik Jung

Hyun Woo Oh

Seung Ho Kim

Sang Ki Kim

Joongku Lee

Beom Su Park

Byung Sun Min

Ik Hwan Kim

InPyo Choi

Goo Taeg Oh

Jung Joo Hong

Soo Yong Kim

Hyun-Jun Lee

Hyeong-Kyu Lee

Guang Hai Shen

Seong Kyu Park

Jin Soo Yook

Woo Namkung

Se Young Chong

Fifit Juniarti

Rifatul Widjhati

Hui Seong Kim

Li Wan Yi

Jin Hyub Paik

Jin Hang

Piseth Khiev

Jae Jong Go

Jang Mi Sun

Hye Suk Lee

In-Sik Shin

Jae Mine Yoo

Ho-Bum Kang

Byoung Whui Choi

Yi Hua Pei

Cheol Jung Lee

Yoosik Yoon

Yong Yeon Cho

Jang Mi Son

Chan Mi Chun

The present invention relates to a pharmaceutical composition containing a monoacetyldiacyiglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.

Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma

The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.

Composition containing monoacetyldiacylglycerol compound as active ingredient for inhibiting blood cancer or metastasis

The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating chronic obstructive pulmonary diseases, and a functional health food composition for treating or preventing chronic obstructive pulmonary diseases. The monoacetyldiacylglycerol compound of the present invention inhibits the IL-4 expression in EL-4 cells and inhibits the infiltration of inflammatory cells into the bronchial tube in an animal model. In addition, the compounds of the present invention have an excellent effect of inhibiting the expression of CXCL-1, TNF-&#x3b1;, or MIP-2, thereby overcoming side effects of the currently used therapeutic agents for chronic obstructive pulmonary diseases, having no toxicity, and exhibiting a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating chronic obstructive pulmonary diseases.

Composition containing monoacetyldiglyceride compound as active ingredient for preventing or treating chronic obstructive pulmonary disease

The present invention relates to a composition for suppressing chronic obstructive pulmonary disease (COPD) comprising aextract, a fraction thereof, or a compound isolated therefrom and, more particularly, to a pharmaceutical composition for preventing or treating COPD comprising aextract, a fraction thereof, or a compound isolated therefrom; a food composition for preventing or improving COPD, and the compound isolated therefrom. The composition comprising aextract, a fraction thereof, or a compound isolated therefrom, according to the present invention, is not toxic, suppresses the invasion of inflammatory cells into the bronchial tube of a COPD-induced animal model, and effectively suppresses the expression of CXCL-1, TNF-&#x3b1;, or MIP-2. In addition, due to the use of a safety-proven herbal drug as a raw material, the composition of the present invention can resolve various side-effects of existing therapeutic agents for COPD, chronic obstructive bronchitis, chronic bronchiolitis, emphysema, multiple sclerosis, and acute and chronic inflammation, and thus can be effectively used as a composition for preventing, treating and remedying COPD.

Pharmaceutical composition comprisingextract, fraction of same or compound separated from same for preventing or treating chronic obstructive pulmonary disease (COPD)

The present invention relates to a composition for preventing or treating asthma comprising aJ. Poiss. ex Franch extract or a fraction thereof. TheJ. Poiss. ex Franch extract or the fraction thereof according to the present invention does not exhibit toxicity, inhibits the generation of NO, IL-4, IL-5, and IL-13 and the generation of reactive oxygen species in the bronchial tubes, and has significantly induced the alleviation of airway hyperresponsiveness, inhibition of the infiltration of inflammatory cells into the bronchial tubes, and reduction of inflammatory cells in bronchoalveolar lavage fluid in an ovalbumin-induced asthma mouse model. In addition, theJ. Poiss. ex Franch extract or the fraction thereof according to the present invention effectively inhibits the secretion of immunoglobulins in serum, secretion of mucus in the bronchial tubes, and infiltration of inflammatory cells into lung tissue and thus can be usefully used as a safe preparation for preventing and treating asthma.

Pharmaceutical composition for preventing or treating asthma comprisingJ. Poiss. ex Franch extract or fraction thereof

A pharmaceutical composition includes any of an extract of, a fraction or an active fraction obtained by fractionation thereof with an organic solvent, and a compound separated therefrom as an active ingredient. The extract of, the fraction or the active fraction obtained by fractionation thereof with an organic solvent, or the compound separated therefrom inhibits the expression of MUC5AC induced by TNF-&#x3b1; and the promoter activity in human lung cancer mucosal cells (H292), reduces the number of inflammatory cells in the bronchoalveolar lavage fluid of the chronic obstructive pulmonary disease mouse model, inhibits the production of reactive oxygen species, and reduces the cytokines; and therefore are effective in preventing or treating chronic obstructive pulmonary disease.

Pharmaceutical composition for preventing and treating chronic obstructive lung disease containing, as active ingredient,extract, fraction, or active fraction thereof

A composition comprising a purified extract isolated fromvar.containing abundant amount of active ingredient or the compounds isolated therefrom as an active ingredient for treating a chronic obstructive pulmonary disease and the use thereof. Inventive purified extract and compounds showed potent anti-COPD activity without beta-2-receptor agonistic response through various in vivo tests as well as in vitro test. Therefore, it can be used as the therapeutics or functional health food for treating and preventing chronic obstructive pulmonary disease (COPD).

Method of treating chronic obstructive pulmonary disease (CPD) with verproside

The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.

The present invention relates to a novel 2-phenylbenzofuran derivative or a pharmaceutically acceptable salt thereof, a production method for the same, and a pharmaceutical composition for preventing or treating an inflammatory disease comprising the same as an active ingredient, and the novel 2-phenylbenzofuran derivative or the pharmaceutically acceptable salt thereof according to the present invention is outstandingly effective in suppressing NO, IL-6, and TNF-alpha induced by macrophages, and therefore can advantageously be used in a pharmaceutical composition for preventing or treating an inflammatory disease.

2-phenylbenzofuran derivatives, method for preparing the same and use of the same for treating inflammatory disease

The invention relates to pharmaceutical compositions, as well as health functional food compositions and quasi-drug compositions, for preventing, treating, or improving rheumatoid arthritis, comprising a monoacetyldiacylglycerol compound as an active ingredient. The monoacetyldiacylglycerol of the invention is effective in inhibiting the phosphorylation of STAT-3 known to be a therapeutic target for rheumatoid arthritis. As the monoacetyldiacylglycerol is an effective therapeutic agent without toxicity, the monoacetyldiacylglycerol can overcome the side effects of the medicines currently used in the treatment of rheumatoid arthritis. Thus, the monoacetyldiacylglycerol can be used for preventing, treating or improving rheumatoid arthritis.

Compositions containing monoacetyldiacylglycerol compound as an active ingredient for preventing or treating rheumatoid arthritis

The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating cancer. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating cancer including a lignan compound having a specific chemical structure (Chemical Formula 1); a health functional food composition for preventing or ameliorating cancer including the lignan compound; and a method for preventing, ameliorating, or treating cancer using the composition. Further, the present invention relates to a use of the lignan compound in the preparation of a pharmaceutical composition or a health functional food composition for preventing, ameliorating, or treating cancer.

Composition containing lignan compound as active ingredient for preventing or treating cancer

The present invention relates to a pharmaceutical composition, functional health food composition, quasi-drug composition, and cosmetic composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing, treating or improving atopic dermatitis. The monoacetyldiacylglycerol compound of the present invention has an excellent effect of suppression of IL-4 and IgE secretion, thereby overcoming side effects of an atopic dermatitis treatment agent currently in use, having no toxicity, and exhibiting an excellent treatment effect, and thus can be useful as a composition for preventing, treating, and ameliorating atopic dermatitis.

Composition containing monoacetyldiglyceride compound as active ingredient for preventing or treating atopic dermatitis

[object Object]

The present invention relates to a pharmaceutical composition for preventing or treating inflammatory diseases or asthma comprising aextract or a fraction thereof as an active ingredient, and a health functional food and a feed additive for preventing or improving inflammatory diseases or asthma comprising the extract or the fraction as an active ingredient.

Pharmaceutical composition for preventing or treating inflammatory diseases or asthma, containing lagerstroemia ovalifolia extract or fraction thereof as active ingredient

Growing community of inventors

Daejeon, South Korea

Kyung Seop Ahn